Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))

Cristian Rodriguez-Aguayo, Emine Bayraktar, Cristina Ivan, Burcu Aslan, Junhua Mai, Guangan He, Lingegowda S. Mangala, Dahai Jiang, Archana S. Nagaraja, Bulent Ozpolat, Arturo Chavez-Reyes, Mauro Ferrari, Rahul Mitra, Zahid H. Siddik, Haifa Shen, Xianbin Yang, Anil K. Sood, Gabriel Lopez-Berestein

Research output: Contribution to journalComment/debatepeer-review

Abstract

The authors noticed that in Figure 6B, the TUNEL staining panel for the “PTGER3 siRNA” group was inadvertently duplicated in the next position for the group of “2’F-PS2-PTGER3 siRNA”. Below is the corrected version of Figure 6B TUNEL staining panels with a new representative image for the 2’F-PS2-PTGER3 siRNA group. This change does not affect the results or conclusions. The authors apologize for any inconvenience caused.

Original languageEnglish (US)
Article number104194
JournalEBioMedicine
Volume83
DOIs
StatePublished - Sep 2022

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Corrigendum to “PTGER3 induces ovary tumorigenesis and confers resistance to cisplatin therapy through up-regulation Ras-MAPK/Erk-ETS1-ELK1/CFTR1 axis” [EBioMedicine 40 (2019) 290-304, (EBioMedicine (2019) 40(290-304) (S2352396418305498), (10.1016/j.ebiom.2018.11.045))'. Together they form a unique fingerprint.

Cite this